Merck's Emend Granted Broad Coverage Under Medicare Part B
This article was originally published in The Pink Sheet Daily
Executive Summary
The oral anti-emetic will be covered by Part B for first-line use in combination with dexamethasone and a 5-HT3 antagonist in patients receiving any of nine highly emetogenic chemotherapy agents under a final coverage decision memo. CMS loosens conditions for reimbursement in response to comments.
You may also be interested in...
CMS Reviewing Aprepitant NCD To Add Use With Moderately Emetogenic Chemo
The current Medicare Part B national coverage determination says use of the anti-nausea drug with highly emetogenic anti-cancer chemotherapy is reasonable and necessary; the National Comprehensive Cancer Network asks CMS to update the NCD based on evidence supporting use with moderately emetogenic agents.
Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision
The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability